Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01103505 · ClinicalTrials.gov registry record · NA
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
A NA study, sponsored by Notal Vision.
- Completed
- Registry status
- NA
- Development phase
- 1,520
- Enrollment target
NCT01103505 is a NA study that has completed, run by Notal Vision. The registered enrollment target is 1,520 participants.
The verdict
NCT01103505, a NA study, has completed, sponsored by Notal Vision.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,520 participants
- Enrollment target
Study Summary
The overall objective of this two arm randomized clinical trial (RCT) is to determine if home monitoring using the comprehensive visual field and telemedicine solution based on the ForeseeHome device in AREDS2 improves detection of progression to choroidal neovascularization (CNV) when compared with standard care.
Interventions
- DIAGNOSTIC_TEST ForeseeHome AMD Monitoring Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,520 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01103505
The ClinicalTrials.gov registry entry for NCT01103505 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,520 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Notal Vision, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ForeseeHome AMD Monitoring Device is the first listed.
NCT01103505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01103505 about?
NCT01103505 is a clinical study titled "HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device". The overall objective of this two arm randomized clinical trial (RCT) is to determine if home monitoring using the comprehensive visual field and telemedicine solution based on the ForeseeHome device in AREDS2 improves detection of progression to choroidal neovascularization (CNV) when compared with...
What is the current status of trial NCT01103505?
This trial is currently completed. It is a NA study. The enrollment target is 1,520 participants. The study started on 2010-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01103505?
The interventions under investigation include: ForeseeHome AMD Monitoring Device (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT01103505?
This trial is sponsored by Notal Vision, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.